BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22584460)

  • 1. Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin.
    Iacobucci I; Lonetti A; Candoni A; Sazzini M; Papayannidis C; Formica S; Ottaviani E; Ferrari A; Michelutti A; Simeone E; Astolfi A; Abbenante MC; Parisi S; Cattina F; Malagola M; Russo D; Damiani D; Gherlinzoni F; Gottardi M; Baccarani M; Fanin R; Martinelli G
    Pharmacogenomics J; 2013 Aug; 13(4):335-41. PubMed ID: 22584460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
    Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
    Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.
    Candoni A; Papayannidis C; Martinelli G; Simeone E; Gottardi M; Iacobucci I; Gherlinzoni F; Visani G; Baccarani M; Fanin R
    Am J Hematol; 2018 May; 93(5):655-663. PubMed ID: 29396857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients.
    Clavio M; Vignolo L; Albarello A; Varaldo R; Pierri I; Catania G; Balocco M; Michelis G; Miglino M; Manna A; Balleari E; Carella AM; Sessarego M; Van Lint MT; Bacigalupo A; Gobbi M
    Br J Haematol; 2007 Jul; 138(2):186-95. PubMed ID: 17593025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".
    Clavio M; Cruciani F; Minetto P; Guolo F; Ballerini F; Marani C; De Astis E; Aquino S; Bergamaschi M; Mitscheunig L; Grasso R; Colombo N; Ghiggi C; Lovera D; Pastori G; Avenoso D; Miglino M; Gobbi M
    Ann Hematol; 2013 Oct; 92(10):1309-18. PubMed ID: 23686116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients.
    Pirrotta MT; Bocchia M; Bucalossi A; Defina M; Forconi F; Gozzetti A; Lauria F
    Acta Haematol; 2007; 118(1):7-9. PubMed ID: 17389781
    [No Abstract]   [Full Text] [Related]  

  • 7. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
    Martin MG; Augustin KM; Uy GL; Welch JS; Hladnik L; Goyal S; Tiwari D; Monahan RS; Reichley RM; Cashen AF; Stockerl-Goldstein K; Westervelt P; Abboud CN; Dipersio JF; Vij R
    Am J Hematol; 2009 Nov; 84(11):733-7. PubMed ID: 19806665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study.
    Usui N; Takeshita A; Nakaseko C; Dobashi N; Fujita H; Kiyoi H; Kobayashi Y; Sakura T; Yahagi Y; Shigeno K; Ohwada C; Miyazaki Y; Ohtake S; Miyawaki S; Naoe T; Ohnishi K;
    Cancer Sci; 2011 Jul; 102(7):1358-65. PubMed ID: 21585619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
    Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.
    Lamba JK; Chauhan L; Shin M; Loken MR; Pollard JA; Wang YC; Ries RE; Aplenc R; Hirsch BA; Raimondi SC; Walter RB; Bernstein ID; Gamis AS; Alonzo TA; Meshinchi S
    J Clin Oncol; 2017 Aug; 35(23):2674-2682. PubMed ID: 28644774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.
    Stone RM; Moser B; Sanford B; Schulman P; Kolitz JE; Allen S; Stock W; Galinsky I; Vij R; Marcucci G; Hurd D; Larson RA;
    Leuk Res; 2011 Mar; 35(3):329-33. PubMed ID: 20688393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy.
    Mortland L; Alonzo TA; Walter RB; Gerbing RB; Mitra AK; Pollard JA; Loken MR; Hirsch B; Raimondi S; Franklin J; Pounds S; Cao X; Rubnitz JE; Ribeiro RC; Gamis A; Meshinchi S; Lamba JK
    Clin Cancer Res; 2013 Mar; 19(6):1620-7. PubMed ID: 23444229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients.
    Borthakur G; Ravandi F; Patel K; Wang X; Kadia T; DiNardo C; Garcia-Manero G; Pemmaraju N; Jabbour EJ; Takahashi K; Ohanian M; Daver N; Alvarado Y; Brandt M; Pierce S; Kantarjian H
    Am J Hematol; 2022 Nov; 97(11):1427-1434. PubMed ID: 36053747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CAG-GO therapy for patients with relapsed or primary refractory CD33-positive acute myelogenous leukemia].
    Takahashi W; Nakamura Y; Tadokoro J; Handa T; Arai H; Tokita K; Iso H; Tsurumi S; Sasaki K; Maki K; Mitani K
    Rinsho Ketsueki; 2012 Jan; 53(1):71-7. PubMed ID: 22374527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.
    Gbadamosi M; Meshinchi S; Lamba JK
    Future Oncol; 2018 Dec; 14(30):3199-3213. PubMed ID: 30039981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
    Tsimberidou A; Cortes J; Thomas D; Garcia-Manero G; Verstovsek S; Faderl S; Albitar M; Kantarjian H; Estey E; Giles FJ
    Leuk Res; 2003 Oct; 27(10):893-7. PubMed ID: 12860008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular response in two children with relapsed acute myeloid leukemia treated with a combination of gemtuzumab ozogamicin and cytarabine.
    Brethon B; Auvrignon A; Cayuela JM; Lapillonne H; Leverger G; Baruchel A
    Haematologica; 2006 Mar; 91(3):419-21. PubMed ID: 16531270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.
    Burnett AK; Hills RK; Milligan D; Kjeldsen L; Kell J; Russell NH; Yin JA; Hunter A; Goldstone AH; Wheatley K
    J Clin Oncol; 2011 Feb; 29(4):369-77. PubMed ID: 21172891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
    Tanaka M; Kano Y; Akutsu M; Tsunoda S; Izumi T; Yazawa Y; Miyawaki S; Mano H; Furukawa Y
    Anticancer Res; 2009 Nov; 29(11):4589-96. PubMed ID: 20032408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
    Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
    Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.